Comparison of clinicopathologic and survival characteristics of high grade endometrial cancers; single center experience.

Abstract

Approximately a quarter of endometrial cancers are of high grade. We aimed to perform clinicopathologic and survival evaluation of high grade endometrial cancer in our study.

We evaluated the data of 78 high grade patients; 30 G3EC (Grade 3 Endometrioid Carcinoma), 48 nonendometrioid carcinomas; 32 USC (uterine serous carcinoma), 16 CCC (clear cell carcinoma), from 312 patients who were followed with endometrial cancer between years 2006 and 2016.

Mean age was 62 years (range 43-83) in all patients, the age in histologic subtypes was 56.5, 65, 66.3, years for G3EC, USC, and CCC, respectively. The G3EC mean age is significantly smaller than other histologic subtypes (P = 0.00). The median follow-up time was 39 months (range 6-136). The 5-year overall survival was 55%, 44%, G3EC, and nonendometrioid carcinoma (USC and CCC), respectively (P = 0.127). In the univariate model; age > 65, ECOG-PS ≥ 2, stage 3-4 disease, LVI presence were poor prognostic factors (P < 0.05). Effect of the stage of the disease, the age of the patients and ECOG-PS on survival was demonstrated with multivariate analysis. The clinicopathologic features of the patients were similar.

G3EC is seen at a younger age than other high grade endometrial carcinomas. Grade 3 endometrioid carcinomas have an increasing trend in survival compared to high grade nonendometrioid carcinomas.